Medicare Will Cover Provenge Labeled Uses, CMS Proposes; Off-Label Is Up To Contractors
This article was originally published in The Pink Sheet Daily
Agency decides against requiring coverage with evidence development for off-label uses.
You may also be interested in...
Modification to ‘reasonable and necessary’ definition in MCIT final rule offers new avenue for drug manufacturers to get products covered in Part B. The Biden Administration will have to decide whether it will keep the Trump regulation unchanged.
Draft national coverage decision addresses current indications and hospital sites of care. CMS expects to “leverage” existing FDA post-market data collection requirements but seeks additional data on patient-reported outcomes in some cases.
Medicare begins analysis process for CAR-T cancer therapies in response to a request from UnitedHealthcare for a national coverage policy.